Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.55 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.48 |
| ▸ | GLB1 | P16278 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834668 | 0.98 | GUSB (0.59) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL9946206 | 0.93 | — | — | |
| SCHEMBL20324860 | 0.85 | GNAO1 (0.58) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL38663658 | 0.84 | GUSB (0.59) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL27321548 | 0.83 | GNAO1 (0.61) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL38666628 | 0.83 | GNAO1 (0.61) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL21759481 | 0.83 | GNAO1 (0.61) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL21933451 | 0.83 | GNAO1 (0.61) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL6888563 | 0.82 | — | — | |
| SCHEMBL23767404 | 0.80 | GUSB (0.59) | GUSBEBPSIGMAR1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | GUSB 2652/4885EBP 3342/4885SIGMAR1 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.